Navigation Links
Medizone International, Inc. Has Filed for Patent Protection for Its AsepticSure(TM) Hospital Sterilization System
Date:7/13/2009

SAN FRANCISCO, July 13 /PRNewswire-FirstCall/ -- Following months of engineering development and laboratory research Medizone (MZEI.PK) has filed what it believes to be a very solid patent application for the Company's lead product AsepticSure(TM). Medizone's CEO Edwin Marshall stated, "This U.S. priority patent application establishes protection of our commercial rights to this technology Internationally. We had two different firms specializing in patent law independently research the existing art in this area so that we had a clear understanding on how to proceed from the beginning. Fortunately, the creative work done by our science and engineering teams has proven these new and innovative combinations of technology when combined have greatly enhanced bactericidal kill rates with all of the pathogens tested so far. This is not just pumping ozone gas into a room. This patent filing not only identifies a number of unique technologies and their protocols, it provides the scientific data proving our ability to obtain 4.4 log/99.994% to 5 log/99.999% kill rates for all of the pathogens of concern in hospital acquired infections. This patent covers disinfection for rooms and their contents within all healthcare facilities, mobile or stationary, and other critical infrastructure such as schools and government buildings. Even as the Company prepares to move into hospital testing later this year, we will continue to work in our new laboratory gaining additional knowledge not only about the pathogens we have already demonstrated outstanding success with, but against a long list of other agents that might provide the Company with significant commercial advantage as we advance the science and practical application of AsepticSure(TM) beyond the hospital environment."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Current trials will now be expanded to include a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are currently targeted to commence by the end of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Investor Relations: 800-953-3350 / web site: www.medizoneint.com

E-mail: operations@medizoneint.com


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.
2. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
3. Medizone Announces a Second Round of Trials Have Begun.
4. Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts
5. Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queens University at Kingston, Ontario, Canada.
6. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
7. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
8. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
9. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
10. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
11. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, ... medicines company, announced today that it entered into ... RNA-based therapeutics for the treatment of NASH and ... therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. ... "Given Takeda,s long-standing commitment to and expertise in ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
(Date:12/6/2016)... A new study released today by the ... the 340B Drug Pricing Program will continue to expand at ... expected to exceed $23 billion in total purchases at the ... current Medicare Part B drug reimbursement purchases over the next ... on analysis of data on total drug purchases through 340B ...
Breaking Medicine Technology: